Online citations, reference lists, and bibliographies.
← Back to Search

Multimodal Management Of Malignant Pleural Mesothelioma: Where Are We Today?

P. V. Van Schil, I. Opitz, W. Weder, C. De Laet, A. Domen, P. Lauwers, J. Hendriks, J. Van Meerbeeck
Published 2014 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
The prognosis of patients with malignant pleural mesothelioma remains poor and although it is clear that multimodal therapy is necessary to improve long-term results, precise treatment schemes have not yet been unequivocally established. Single-modality therapy does not have a major impact on long-term survival and combined-modality therapies are being further evaluated. However, the relative contributions of chemotherapy, radiotherapy and surgery have not been clearly determined at the present time. Moreover, the extent of resection and precise surgical procedure remain a highly debated topic. To better compare and combine results from different institutions and trials, uniform definitions of surgical procedures including extrapleural pneumonectomy and different forms of pleurectomy have recently been introduced. Due to the relatively higher morbidity and mortality of extrapleural pneumonectomy, there is currently a shift towards pleurectomy/decortication when a macroscopic complete resection of all tumour can be obtained by this procedure. In most recent trials, induction chemotherapy was administered to improve surgical resection rates but pathological complete responses are infrequently observed. The role of post-operative radiotherapy has to be further elucidated. Further treatment options that are currently explored include hyperthermic intrapleural chemotherapy, immunotherapy, gene therapy and photodynamic therapy. However, no randomised comparisons are available yet. Treatment of malignant pleural mesothelioma remains controversial http://ow.ly/sNCYl
This paper references
IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Arsenic, metals, fibres, and dusts
(2012)
MesoVATS: a multi-centre randomised controlled trial of video-assited thoracoscopic pleurectomy versus talc pleurodesis in malignant pleural mesothelioma
RCRA Rintoul (2013)
Mesothelioma Interest Group
P. Van Schil (1995)
10.1200/JCO.1998.16.1.145
Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.
D. Curran (1998)
10.1016/j.jtcvs.2012.12.037
Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete resection.
D. Sugarbaker (2013)
mesothelioma database
PE VanSchil (2012)
10.1016/J.RADONC.2007.05.022
A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma.
N. O’Rourke (2007)
chemotherapy in maignant pleural mesothelioma patients
VW Rusch (2013)
10.1038/sj.bjc.6601957
A randomised trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma
S. Bydder (2004)
10.1097/JTO.0b013e318269fe21
Optimization of Response Classification Criteria for Patients with Malignant Pleural Mesothelioma
Z. Labby (2012)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1378/CHEST.108.4.1122
A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group.
V. Rusch (1995)
10.3978/j.issn.2225-319X.2012.11.10
Do we need a revised staging system for malignant pleural mesothelioma? Analysis of the IASLC database.
V. Rusch (2012)
10.1097/JTO.0b013e3181ed0489
A Systematic Review of Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma
C. Cao (2010)
10.1097/JTO.0b013e31826915f1
Initial Analysis of the International Association For the Study of Lung Cancer Mesothelioma Database
V. Rusch (2012)
10.3978/J.ISSN.1000-9604.2013.01.11
Treatment of mesothelioma: still a long way to go!
Van Schil (2013)
10.1200/JCO.2008.20.3943
Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.
L. Krug (2009)
10.1016/j.ijrobp.2011.09.027
Pleural intensity-modulated radiotherapy for malignant pleural mesothelioma.
K. Rosenzweig (2012)
pleuritis. MMCTS 2012; mms008: 10.1093/mmcts/mms008
JC Halstead (2012)
10.1016/j.ejso.2008.06.009
Long-term indwelling pleural catheter (PleurX) for malignant pleural effusion unsuitable for talc pleurodesis.
T. Sioris (2009)
10.1111/j.1759-7714.2012.00127.x
Clinical and biologic prognostic factors in malignant pleural mesothelioma
V. Ambrogi (2012)
10.6004/JNCCN.2012.0006
[Malignant pleural mesothelioma].
Q. Kong (1983)
10.1097/MCP.0b013e3282fcea50
Prophylactic radiotherapy for pleural puncture sites in mesothelioma: the controversy continues
H. E. Davies (2008)
10.1200/JCO.2008.17.5604
Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
M. D. de Perrot (2009)
10.2214/AJR.11.7015
Epithelial malignant pleural mesothelioma after extrapleural pneumonectomy: stratification of survival with CT-derived tumor volume.
R. Gill (2012)
10.3978/j.issn.2225-319X.2012.11.07
Systematic review of trimodality therapy for patients with malignant pleural mesothelioma.
C. Cao (2012)
10.1510/ICVTS.2005.123430
The MARS trial: mesothelioma and radical surgery.
T. Treasure (2006)
Intracavitary Cisplatin-Fibrin Chemotherapy After Resection For Malignant Pleural Mesothelioma Patients (Influence-Meso) - Preliminary Results
I. Opitz (2013)
10.1097/JTO.0b013e31828353d7
Surgery in mesothelioma--where do we go after MARS?
B. Hiddinga (2013)
10.1016/S1010-7940(00)00422-X
The long-term morbidity of pleuroperitoneal shunts in the management of recurrent malignant effusions.
O. Genc (2000)
10.1016/j.soc.2012.12.004
Multimodality treatment of pleural mesothelioma.
David D. Shersher (2013)
10.3978/j.issn.2225-319X.2012.11.14
Radical pleurectomy and photodynamic therapy for malignant pleural mesothelioma.
J. Friedberg (2012)
10.1183/09031936.00168111
Mesothelioma incidence projections in South East England
S. P. Riaz (2012)
10.1093/ANNONC/MDM093
Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
W. Weder (2007)
10.1016/J.LUNGCAN.2005.03.008
Malignant pleural mesothelioma: staging systems.
P. V. Schil (2005)
10.1200/JCO.2005.05.1359
Progression-free survival rate as primary end point for phase II cancer clinical trials: application to mesothelioma--The EORTC Lung Cancer Group.
J. Francart (2006)
10.1002/14651858.CD005574.PUB2
Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma.
J. Green (2007)
10.1093/annonc/mds535
Disease volumes as a marker for patient response in malignant pleural mesothelioma.
Z. Labby (2013)
10.1200/JCO.2013.31.15_SUPPL.7587
A clinical-based risk score for decision making for surgery after induction chemotherapy in malignant pleural mesothelioma patients.
I. Opitz (2013)
10.1097/JTO.0b013e31824ab6c5
Pleurectomy/Decortication is Superior to Extrapleural Pneumonectomy in the Multimodality Management of Patients with Malignant Pleural Mesothelioma
L. Lang-Lazdunski (2012)
10.1093/mmcts/mms008
Subtotal pleurectomy by video-assisted thoracic surgery for metastatic pleuritis.
K. Meuris (2012)
10.1016/S1470-2045(11)70307-2
The MARS feasibility trial: conclusions not supported by data.
W. Weder (2011)
10.1183/09031936.00039510
Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial
P. V. Van Schil (2010)
10.1097/JTO.0B013E318156AF3B
Mesothelioma: benefit from surgical resection is questionable.
T. Treasure (2007)
10.1183/09031936.00063109
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma
A. Scherpereel (2009)
10.1097/JTO.0b013e3182288af9
Pleurectomy/Decortication, Hyperthermic Pleural Lavage with Povidone-Iodine Followed by Adjuvant Chemotherapy in Patients with Malignant Pleural Mesothelioma
L. Lang-Lazdunski (2011)
10.1016/J.RADONC.2006.06.002
The role of radiation therapy in malignant pleural mesothelioma: a systematic review.
Y. Ung (2006)
10.1378/CHEST.113.3.723
Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.
J. Herndon (1998)
10.1097/JTO.0b013e3181ae26ae
The Mesothelioma and Radical Surgery Randomized Controlled Trial: The MARS Feasibility Study
T. Treasure (2009)
10.1183/09031936.00146110
Volumetry: an alternative to assess therapy response for malignant pleural mesothelioma?
T. Frauenfelder (2011)
10.1016/j.jtcvs.2007.10.054
Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.
R. Flores (2008)
10.1016/j.jtcvs.2013.01.039
The role of surgical cytoreduction in the treatment of malignant pleural mesothelioma: meeting summary of the International Mesothelioma Interest Group Congress, September 11-14, 2012, Boston, Mass.
V. Rusch (2013)
EORTC randomised phase II study of extended pleurectomy/ decortication (e-P/D) preceded or followed by (neo-)adjuvant chemotherapy in patients with early stage malignant pleural mesothelioma (MPM)
L Lang-Lazdunski (2012)
10.1016/j.lungcan.2009.06.014
Prophylactic radiotherapy to intervention sites in mesothelioma: a systematic review and survey of UK practice.
C. Lee (2009)
10.1016/j.lungcan.2013.04.024
Systematic review of pleurectomy in the treatment of malignant pleural mesothelioma.
C. Cao (2013)
10.32388/b2g8ub
Cancer and Leukemia Group B
Clinical disciplines (2010)
10.1016/S0039-6109(02)00033-6
Malignant mesothelioma: options for management.
S. Singhal (2002)
Study Using Chemotherapy +/-Pleurectomy/Decortication Followed By Intensity Modulated Radiation Therapy. www.clinicaltrials.gov/ct2/show/NCT00715611 Date last accessed
Memorial Sloan
10.1378/CHEST.108.3.754
Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy.
C. Boutin (1995)
10.1067/MTC.2001.116560
A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
V. Rusch (2001)
10.1200/JCO.20005.14.589
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
J. Van Meerbeeck (2005)
10.1093/ANNONC/MDH059
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.
M. Byrne (2004)
Arsenic, metals, fibres, and dusts.
(2012)
10.1097/JTO.0b013e3182208e3f
Recommendations for Uniform Definitions of Surgical Techniques for Malignant Pleural Mesothelioma: A Consensus Report of the International Association for the Study of Lung Cancer International Staging Committee and the International Mesothelioma Interest Group
D. Rice (2011)
10.1016/j.ccm.2013.04.007
Intracavitary therapeutics for pleural malignancies.
A. Haas (2013)
10.1016/S0022-5223(99)70469-1
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
D. Sugarbaker (1999)
10.1200/JCO.2008.19.8523
Malignant pleural mesothelioma.
A. Tsao (2009)
10.1097/JTO.0b013e31824d9a52
Is it time to consider pleurectomy and decortication as the only surgical treatment for malignant pleural mesothelioma?
M. Weyant (2012)
10.1016/S1470-2045(11)70149-8
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
T. Treasure (2011)
10.1097/JTO.0b013e3182730e0e
Robust data: the essential foundation of a revised staging system for pleural mesothelioma.
H. Kindler (2012)
10.3978/j.issn.1000-9604.2013.01.11
Treatment of mesothelioma: still a long way to go!
P. V. Van Schil (2013)
10.3978/j.issn.2072-1439.2013.11.28
Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.
N. van Zandwijk (2013)
10.1016/j.lungcan.2013.08.005
Imaging in pleural mesothelioma: a review of the 11th International Conference of the International Mesothelioma Interest Group.
S. Armato (2013)
10.1016/J.EJSO.2004.08.014
Improved survival with VATS pleurectomy-decortication in advanced malignant mesothelioma.
J. Halstead (2005)
10.1016/J.ATHORACSUR.2007.04.076
Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma.
D. Rice (2007)
10.1111/j.1440-1843.2005.00714.x
Advances in the diagnosis, evaluation, and management of malignant pleural mesothelioma
D. Sterman (2005)



This paper is referenced by
Inflammation associated cancers and potential therapeutics
Aaron H. Rose (2014)
10.1183/09031936.00126714
Staging of lung cancer: the role of noninvasive, minimally invasive and invasive techniques
G. Stamatis (2015)
10.1080/2162402X.2018.1537427
Versican modulates tumor-associated macrophage properties to stimulate mesothelioma growth
Apostolos G Pappas (2019)
10.3978/j.issn.2072-1439.2014.05.03
Management of malignant pleural mesothelioma-The European experience.
I. Opitz (2014)
10.1007/S00761-014-2886-9
Pleuramesotheliome: Multimodales Management als klinische Herausforderung
Rudolf A. Hatz (2015)
10.1016/j.lungcan.2020.06.024
Questioning the prognostic role of BAP-1 immunohistochemistry in malignant pleural mesothelioma: A single center experience with systematic review and meta-analysis.
L. Cantini (2020)
10.18632/oncotarget.13174
Malignant pleural mesothelioma and mesothelial hyperplasia: A new molecular tool for the differential diagnosis
R. Bruno (2017)
10.1093/jjco/hyv039
A new prognostic index for overall survival in malignant pleural mesothelioma: the rPHS (regimen, PS, histology or stage) index.
Yuki Kataoka (2015)
10.4274/nts.2018.008
The Role of Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Imaging in Mesothelioma
Ö. Özmen (2018)
10.1016/j.lungcan.2017.09.012
External validation of prognostic indices for overall survival of malignant pleural mesothelioma.
Yuki Kataoka (2017)
10.1007/s00595-015-1275-3
Current surgical strategies for malignant pleural mesothelioma
T. Takuwa (2015)
10.1183/13993003.01428-2016
Impact of tumour thickness on survival after radical radiation and surgery in malignant pleural mesothelioma
M. D. de Perrot (2017)
10.5858/arpa.2016-0073-OA
Dataset for Reporting of Malignant Mesothelioma of the Pleura or Peritoneum: Recommendations From the International Collaboration on Cancer Reporting (ICCR).
A. Churg (2016)
10.1080/00015458.2016.1272253
Malignant pleural mesothelioma: single-institution experience of 101 patients over a 15-year period
A. Domen (2017)
10.1183/09031936.00156614
Management of EGFR mutated nonsmall cell lung carcinoma patients
B. Grigoriu (2015)
10.1016/j.cyto.2018.08.006
Role of angiopoietins in mesothelioma progression.
Sophia F Magkouta (2018)
10.1093/annonc/mdv101
Searching for targets for the systemic therapy of mesothelioma.
R. Stahel (2015)
10.21037/tlcr.2017.06.03
Radio-immunotherapy and chemo-immunotherapy as a novel treatment paradigm in malignant pleural mesothelioma.
Licun Wu (2017)
10.1183/09031936.00197013
Tumour tissue sampling for lung cancer management in the era of personalised therapy: what is good enough for molecular testing?
L. Kim (2014)
10.1016/j.jtcvs.2018.10.039
Treatment of malignant pleural mesothelioma with chemotherapy preceding versus after surgical resection
V. Verma (2019)
10.1053/j.semtcvs.2014.08.003
Novel induction therapies for pleural mesothelioma.
L. Donahoe (2014)
10.3978/j.issn.2305-5839.2015.07.03
Advances in the diagnosis, treatment and prognosis of malignant pleural mesothelioma.
Weiquan Zhang (2015)
10.1016/S1877-1203(16)30135-5
Traitement du mésothéliome pleural malin en 2016
A. Scherpereel (2016)
10.21037/tlcr-19-686
Nivolumab in pre-treated malignant pleural mesothelioma: real-world data from the Dutch expanded access program.
Luca Cantini (2020)
10.1038/modpathol.2017.170
Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study
Lauren E. Rosen (2018)
A narrative review of current treatment strategies and emerging therapies in malignant pleural mesothelioma
Élise Di Lena (2020)
10.1183/13993003.00319-2017
Malignant pleural mesothelioma: new treatments, new hopes?
A. Scherpereel (2017)
10.1016/j.freeradbiomed.2015.05.002
Malignant mesothelioma as an oxidative stress-induced cancer: An update.
S. H. Chew (2015)
10.21037/tlcr.2018.07.07
Extrapleural pneumonectomy: still indicated?
A. Domen (2018)
10.1016/j.ejps.2018.07.035
Combined hyaluronate‐based films loaded with pemetrexed and cisplatin for the treatment of malignant pleural mesothelioma: Preliminary evaluation in an orthotopic tumor recurrence model
F. Sonvico (2018)
10.1016/j.lungcan.2018.01.001
Computed tomography in the evaluation of malignant pleural mesothelioma-Association of tumor size to a sarcomatoid histology, a more advanced TNM stage and poor survival.
Juuso Paajanen (2018)
10.1007/s15033-019-1153-6
Multimodale Therapiekonzepte beim malignen Pleuramesotheliom
Laura V. Klotz (2019)
See more
Semantic Scholar Logo Some data provided by SemanticScholar